FOCUS ON ACCESS™ (FOA) helps eligible patients secure access to VISUDYNE® and offers the following services*:
*Terms and conditions apply and can be found on the FOA enrollment form. Please be sure to share eligibility criteria with your patients.
Bausch + Lomb does not guarantee coverage or reimbursement for the product.
VISUDYNE® (verteporfin for injection) therapy is a photoenhancer indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis. There is insufficient evidence to indicate VISUDYNE for the treatment of predominantly occult subfoveal CNV.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Click here for full Prescribing Information for VISUDYNE®.
Indication and Important Safety Information